Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Head- to head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as Reference-Standard.

Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, Mabjeesh NJ, Yossepowitch O, Mishani E, Even-Sapir E.

J Nucl Med. 2019 Sep 27. pii: jnumed.119.234187. doi: 10.2967/jnumed.119.234187. [Epub ahead of print]

PMID:
31562225
2.

[68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?

Kuten J, Sarid D, Yossepowitch O, Mabjeesh NJ, Even-Sapir E.

EJNMMI Res. 2019 Aug 29;9(1):84. doi: 10.1186/s13550-019-0554-1.

3.

68Ga-PSMA PET/CT: Does it predict adverse pathology findings at radical prostatectomy?

Dekalo S, Kuten J, Mabjeesh NJ, Beri A, Even-Sapir E, Yossepowitch O.

Urol Oncol. 2019 Sep;37(9):574.e19-574.e24. doi: 10.1016/j.urolonc.2019.05.015. Epub 2019 Jun 14.

PMID:
31204017
4.

Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification.

Matzkin H, Chen J, Agai R, Ziv-Baran T, Mabjeesh NJ.

PLoS One. 2019 Apr 19;14(4):e0215582. doi: 10.1371/journal.pone.0215582. eCollection 2019.

5.

Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.

Kuten J, Mabjeesh NJ, Lerman H, Levine C, Barnes S, Even-Sapir E.

Isr Med Assoc J. 2019 Feb;21(2):100-104.

6.

β-TrCP upregulates HIF-1 in prostate cancer cells.

Cohen M, Amir S, Golan M, Ben-Neriah Y, Mabjeesh NJ.

Prostate. 2019 Mar;79(4):403-413. doi: 10.1002/pros.23746. Epub 2018 Nov 28.

PMID:
30488478
7.

Septin 9 isoform 1 (SEPT9_i1) specifically interacts with importin-α7 to drive hypoxia-inducible factor (HIF)-1α nuclear translocation.

Tazat K, Schindler S, Depping R, Mabjeesh NJ.

Cytoskeleton (Hoboken). 2019 Jan;76(1):123-130. doi: 10.1002/cm.21450. Epub 2018 Aug 24.

PMID:
29742803
8.

Can urologists accurately stage and grade urothelial bladder cancer by assessing endoscopic photographs?

Dekalo S, Matzkin H, Mabjeesh NJ.

J Telemed Telecare. 2018 Oct;24(9):603-607. doi: 10.1177/1357633X17727773. Epub 2017 Sep 18.

PMID:
28920525
9.

High cancer detection rate using cognitive fusion - targeted transperineal prostate biopsies.

Dekalo S, Matzkin H, Mabjeesh NJ.

Int Braz J Urol. 2017 Jul-Aug;43(4):600-606. doi: 10.1590/S1677-5538.IBJU.2016.0511.

10.

Imaging of hypoxia-inducible factor 1α and septin 9 interaction by bimolecular fluorescence complementation in live cancer cells.

Golan M, Mabjeesh NJ.

Oncotarget. 2017 May 9;8(19):31830-31841. doi: 10.18632/oncotarget.16527.

11.

microRNA expression profiles as decision-making biomarkers in the management of bladder cancer.

Amir S, Mabjeesh NJ.

Histol Histopathol. 2017 Feb;32(2):107-119. doi: 10.14670/HH-11-814. Epub 2016 Sep 2. Review.

PMID:
27586262
12.

High SEPT9_i1 protein expression is associated with high-grade prostate cancers.

Gilad R, Meir K, Stein I, German L, Pikarsky E, Mabjeesh NJ.

PLoS One. 2015 Apr 21;10(4):e0124251. doi: 10.1371/journal.pone.0124251. eCollection 2015.

13.

Is diagnostic cystoscopy painful? Analysis of 1,320 consecutive procedures.

Greenstein A, Greenstein I, Senderovich S, Mabjeesh NJ.

Int Braz J Urol. 2014 Jul-Aug;40(4):533-8. doi: 10.1590/S1677-5538.IBJU.2014.04.13.

14.
15.

SEPT9_i1 is required for the association between HIF-1α and importin-α to promote efficient nuclear translocation.

Golan M, Mabjeesh NJ.

Cell Cycle. 2013 Jul 15;12(14):2297-308. doi: 10.4161/cc.25379.

16.

Forchlorfenuron disrupts SEPT9_i1 filaments and inhibits HIF-1.

Vardi-Oknin D, Golan M, Mabjeesh NJ.

PLoS One. 2013 Aug 19;8(8):e73179. doi: 10.1371/journal.pone.0073179. eCollection 2013.

17.

One stop screening for multiple cancers: the experience of an integrated cancer prevention center.

Sella T, Boursi B, Gat-Charlap A, Aroch I, Liberman E, Moshkowitz M, Miller E, Gur E, Inbar R, Blachar A, Mabjeesh NJ, Rosenfeld O, Sperber F, Reiser V, Kleinman S, Jaffa AJ, Bloch M, Ormianer M, Naumov I, Kazanov D, Kraus S, Galazan L, Arber N.

Eur J Intern Med. 2013 Apr;24(3):245-9. doi: 10.1016/j.ejim.2012.12.012. Epub 2013 Jan 9.

PMID:
23312963
18.
19.

HIF1A C1772T polymorphism leads to HIF-1α mRNA overexpression in prostate cancer patients.

Vainrib M, Golan M, Amir S, Dang DT, Dang LH, Bar-Shira A, Orr-Urtreger A, Matzkin H, Mabjeesh NJ.

Cancer Biol Ther. 2012 Jul;13(9):720-6. Epub 2012 May 31.

PMID:
22647679
20.

High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound-guided template saturation biopsy.

Mabjeesh NJ, Lidawi G, Chen J, German L, Matzkin H.

BJU Int. 2012 Oct;110(7):993-7. doi: 10.1111/j.1464-410X.2012.10972.x. Epub 2012 Mar 6.

21.

Validation and comparison of the two Kattan nomograms in patients with prostate cancer treated with (125) iodine brachytherapy.

Kaplan A, German L, Chen J, Matzkin H, Mabjeesh NJ.

BJU Int. 2012 Jun;109(11):1661-5. doi: 10.1111/j.1464-410X.2011.10748.x. Epub 2011 Nov 24.

22.

Hypoxia induces PTHrP gene transcription in human cancer cells through the HIF-2α.

Manisterski M, Golan M, Amir S, Weisman Y, Mabjeesh NJ.

Cell Cycle. 2010 Sep 15;9(18):3723-9. Epub 2010 Sep 7.

PMID:
20890122
23.

Long-term results of early endoscopic realignment of complete posterior urethral disruption.

Sofer M, Mabjeesh NJ, Ben-Chaim J, Aviram G, Bar-Yosef Y, Matzkin H, Kaver I.

J Endourol. 2010 Jul;24(7):1117-21. doi: 10.1089/end.2010.0069.

PMID:
20590470
24.

The role of brachytherapy in the 21st century for prostate cancer.

Mabjeesh NJ, Matzkin H.

Minerva Urol Nefrol. 2010 Jun;62(2):203-11. Review.

PMID:
20562800
25.

Targeted knockdown of SEPT9_v1 inhibits tumor growth and angiogenesis of human prostate cancer cells concomitant with disruption of hypoxia-inducible factor-1 pathway.

Amir S, Golan M, Mabjeesh NJ.

Mol Cancer Res. 2010 May;8(5):643-52. doi: 10.1158/1541-7786.MCR-09-0497. Epub 2010 Apr 20.

26.

Prospective comparison of PSA kinetics following two different prostate cancer brachytherapy planning methods: preoperative and real-time intraoperative dosimetry planning.

Matzkin H, Chen J, Stenger A, Agai R, Mabjeesh NJ.

Urol Oncol. 2012 Jul-Aug;30(4):379-85. doi: 10.1016/j.urolonc.2009.12.001. Epub 2010 Mar 2.

PMID:
20189847
27.

Detection of prostate specific transcripts in the peripheral blood during brachytherapy predicts postoperative PSA kinetics.

Mabjeesh NJ, Amir S, Stenger A, Chen J, Matzkin H.

Prostate. 2009 Aug 1;69(11):1235-44. doi: 10.1002/pros.20977.

PMID:
19434652
28.

SEPT9_v1 up-regulates hypoxia-inducible factor 1 by preventing its RACK1-mediated degradation.

Amir S, Wang R, Simons JW, Mabjeesh NJ.

J Biol Chem. 2009 Apr 24;284(17):11142-51. doi: 10.1074/jbc.M808348200. Epub 2009 Feb 26.

29.

[Alpha blockers in use for symptomatic benign prostatic hyperplasia--are all drugs born equal?].

Bar-Yosef Y, Mabjeesh NJ, Laufer M, Neulander EZ, Kaver I, Matzkin H.

Harefuah. 2008 Jun;147(6):514-9, 574. Review. Hebrew.

PMID:
18693628
30.

Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition.

Dang DT, Chun SY, Burkitt K, Abe M, Chen S, Havre P, Mabjeesh NJ, Heath EI, Vogelzang NJ, Cruz-Correa M, Blayney DW, Ensminger WD, St Croix B, Dang NH, Dang LH.

Cancer Res. 2008 Mar 15;68(6):1872-80. doi: 10.1158/0008-5472.CAN-07-1589.

31.

Potentiation of 2-methoxyestradiol-induced cytotoxicity by blocking endothelin A receptor in prostate cancer cells.

Mabjeesh NJ, Shefler A, Amir S, Matzkin H.

Prostate. 2008 May 1;68(6):679-89. doi: 10.1002/pros.20734.

PMID:
18288682
32.

SEPT9_V1 protein expression is associated with human cancer cell resistance to microtubule-disrupting agents.

Amir S, Mabjeesh NJ.

Cancer Biol Ther. 2007 Dec;6(12):1926-31. Epub 2007 Sep 1.

PMID:
18075300
33.

Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.

Mabjeesh NJ, Chen J, Stenger A, Matzkin H.

Urology. 2007 Sep;70(3):548-53.

PMID:
17905113
34.

Extending the application of tubeless percutaneous nephrolithotomy.

Sofer M, Beri A, Friedman A, Aviram G, Mabjeesh NJ, Chen J, Ben-Chaim J, Greenstein A, Matzkin H.

Urology. 2007 Sep;70(3):412-6; discussion 416-7.

PMID:
17905084
35.

1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells.

Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ.

Mol Cancer Ther. 2007 Apr;6(4):1433-9.

36.

Hypoxia-inducible factor (HIF) in human tumorigenesis.

Mabjeesh NJ, Amir S.

Histol Histopathol. 2007 May;22(5):559-72. doi: 10.14670/HH-22.559. Review.

PMID:
17330811
37.
38.

Are consecutive nightly recordings required for valid evaluation of sleep-associated erections?

Greenstein A, Mabjeesh NJ, Sofer M, Kaver I, Matzkin H, Chen J.

Int J Impot Res. 2007 Mar-Apr;19(2):196-9. Epub 2006 Aug 3.

PMID:
16885991
39.
40.
41.

Per urethra insertion of a through-and-through safety guide wire using a dual-lumen ureteral catheter during percutaneous nephrolithotripsy.

Greenstein A, Sofer M, Mabjeesh NJ, Kaver I, Matzkin H.

Int Urol Nephrol. 2004;36(3):317-8.

PMID:
15783093
42.
43.

Endourologic procedures combined with other surgical and urologic interventions--early experience.

Sofer M, Kaver I, Chen J, Nadu A, Beri A, Mabjeesh NJ, Greenstein A, Matzkin H.

Urology. 2004 Nov;64(5):900-3.

PMID:
15533474
44.

Refinements in treatment of large bladder calculi: simultaneous percutaneous suprapubic and transurethral cystolithotripsy.

Sofer M, Kaver I, Greenstein A, Bar Yosef Y, Mabjeesh NJ, Chen J, Ben-Chaim J, Matzkin H.

Urology. 2004 Oct;64(4):651-4.

PMID:
15491692
45.

Spermatic vein tumor thrombus in renal cell carcinoma.

Mabjeesh NJ, Bar-Yosef Y, Schreiber-Bramante L, Kaver I, Matzkin H.

ScientificWorldJournal. 2004 Jun 7;4 Suppl 1:192-4.

46.

Are indications for prostatectomy in octogenarians the same as for younger men?

Nadu A, Mabjeesh NJ, Ben-Chaim J, Kaver I, Matzkin H, Greenstein A.

Int Urol Nephrol. 2004;36(1):47-50.

PMID:
15338673
47.

HIF at the crossroads between ischemia and carcinogenesis.

Paul SA, Simons JW, Mabjeesh NJ.

J Cell Physiol. 2004 Jul;200(1):20-30. Review.

PMID:
15137054
48.
49.

Biotechnology and drug discovery: from bench to bedside.

Avidor Y, Mabjeesh NJ, Matzkin H.

South Med J. 2003 Dec;96(12):1174-86. Review.

PMID:
14696868
50.

Supplemental Content

Loading ...
Support Center